Provided by Tiger Trade Technology Pte. Ltd.

Lixte Biotechnology Holdings Inc.

3.00
-0.0200-0.66%
Volume:8.32K
Turnover:25.09K
Market Cap:26.11M
PE:-2.48
High:3.10
Open:3.10
Low:3.00
Close:3.02
52wk High:6.26
52wk Low:0.6400
Shares:8.70M
Float Shares:7.99M
Volume Ratio:0.29
T/O Rate:0.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2110
EPS(LYR):-1.5943
ROE:-130.06%
ROA:-68.32%
PB:11.07
PE(LYR):-1.88

Loading ...

Lixte Subsidiary Liora Technologies Europe Names Sidney Braun CEO

Reuters
·
Yesterday

Lixte Biotechnology Appoints Sidney Braun as CEO of Its Liora Technologies Europe Ltd. Subsidiary

THOMSON REUTERS
·
Yesterday

LIXTE Biotechnology (NASDAQ: LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment

TIPRANKS
·
Feb 10

Improving the Odds: How LIXTE Biotechnology (NASDAQ: LIXT) Is Working to Make Cancer Therapies More Effective

TIPRANKS
·
Feb 06

LIXTE Biotechnology Holdings (NASDAQ: LIXT) Advances a Novel Approach to Enhancing Cancer Therapy

TIPRANKS
·
Jan 24

LIXTE Biotechnology Holdings (NASDAQ: LIXT) Sponsors Good Health Mind, Body and Soul Summit

TIPRANKS
·
Jan 22

Lixte Biotechnology Holdings to Participate in DealFlow Discovery Conference in Atlantic City

Reuters
·
Jan 20

LIXTE Biotechnology Holdings (NASDAQ: LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK

TIPRANKS
·
Jan 09

Lixte Biotechnology Announces Unregistered Share Exchange with Orbit Capital

Reuters
·
Jan 01

Lixte Biotechnology Holdings Inc - Expands Collaboration With University of Texas Md Anderson Cancer Center & GSK for Lb-100

THOMSON REUTERS
·
Dec 23, 2025

Lixte Biotechnology Expands Ovarian Cancer Trial With MD Anderson and GSK

Reuters
·
Dec 23, 2025

Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

GlobeNewswire
·
Dec 18, 2025

Lixte Biotechnology Holdings Inc. held annual shareholder meeting

Reuters
·
Dec 12, 2025

Lixte Biotechnology Holdings Inc. Outlines Strategy to Expand Oncology Platform with Complementary Modalities, Advancing PP2A Inhibitor Development and Integrating Radiotherapy Technologies

Reuters
·
Dec 08, 2025

Lixte Biotechnology Holdings Inc. Outlines Strategy to Advance LB-100 Combination Therapy, Strengthen Financial Foundation, and Support Multi-Year Clinical Development

Reuters
·
Dec 03, 2025

Lixte Biotechnology Acquires Liora Technologies for Growth

TIPRANKS
·
Nov 26, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Applied Materials, CDW,  Kohl's

Reuters
·
Nov 25, 2025

BUZZ-Lixte rises after buying UK firm to enter proton therapy cancer care

Reuters
·
Nov 25, 2025

Lixte Biotechnology acquires Liora’s proton therapy platform

TIPRANKS
·
Nov 25, 2025

Lixte Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment

THOMSON REUTERS
·
Nov 25, 2025